ISCA, CHRYSTEL

ISCA, CHRYSTEL  

Mostra records
Risultati 1 - 20 di 22 (tempo di esecuzione: 0.022 secondi).
Titolo Data di pubblicazione Autore(i) File
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 1-gen-2018 Pozzi, S.; Belletti, L.; Cortesi, L.; Moscetti, L.; Omarini, C.; Piacentini, F.; Toss, A.; Caputo, Francesco; Greco, S.; Isca, C.; Napolitano, M.; Tarantino, V.; Malinverni, C.; Checchi, Eleonora; Mascia, Maria Teresa; Cascinu, S
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 1-gen-2021 Toss, Angela; Spinella, Amelia; Isca, Chrystel; Vacchi, Caterina; Ficarra, Guido; Fabbiani, Luca; Iannone, Anna; Magnani, Luca; Castrignanò, Paola; Macripo', Pierluca; Gasparini, Elisa; Piana, Simonetta; Cortesi, Laura; Maiorana, Antonino; Salvarani, Carlo; Dominici, Massimo; Giuggioli, Dilia
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 1-gen-2021 Toss, Angela; Spinella, Amelia; Isca, Chrystel; Vacchi, Caterina; Ficarra, Guido; Fabbiani, Luca; Iannone, Anna; Magnani, Luca; Castrignanò, Paola; Macripò, Pierluca; Gasparini, Elisa; Piana, Simonetta; Cortesi, Laura; Maiorana, Antonino; Salvarani, Carlo; Dominici, Massimo; Giuggioli, Dilia
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 1-gen-2020 Isca, Chrystel; Omarini, Claudia; Cortesi, Giulia; Moscetti, Luca; Barbolini, Monica; Dominici, Massimo; Piacentini, Federico
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 1-gen-2019 Barbolini, M; Omarini, C; Viola, L; Isca, C; Marchi, I; Caggia, F; Barbieri, E; Toss, A; Cortesi, L; Dominici, M; Piacentini, F.
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 1-gen-2020 Omarini, C.; Piacentini, F.; Sperduti, I.; Barbolini, M.; Isca, C.; Toss, A.; Cortesi, L.; Barbieri, E.; Dominici, M.; Moscetti, L.
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 1-gen-2019 Omarini, C; Bettelli, S; Caprera, C; Manfredini, S; Barbolini, M; Moscetti, L; Isca, C; Toss, A; Barbieri, E; Cortesi, L; Kaleci, S; Maiorana, A; Tazzioli, G; Cascinu, S; Piacentini, F
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients. 1-gen-2021 Del Re, M; Omarini, C; Diodati, L; Palleschi, M; Meattini, I; Crucitta, S; Lorenzini, G; Isca, C; Fontana, A; Livi, L; Piacentini, F; Fogli, S; De Giorgi, U; Danesi, R.
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 1-gen-2018 Toss, A.; Venturelli, M.; Sperduti, I.; Isca, C.; Barbieri, E.; Piacentini, F.; Omarini, C.; Cortesi, L; Cascinu, Stefano; Moscetti, L.
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 1-gen-2019 Omarini, C; Sperduti, I; Barbolini, M; Isca, C; Bocconi, Alessandro; Toss, A; Cortesi, L; Barbieri, E; Piacentini, F; Cascinu, S; Moscetti, L
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 1-gen-2019 Omarini, Claudia; Piacentini, Federico; Sperduti, Isabella; Barbolini, Monica; Isca, Chrystel; Nasso, Cecilia; Toss, Angela; D'Onofrio, Raffaella; Cortesi, Laura; Barbieri, Elena; Cascinu, Stefano; Moscetti, Luca
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 1-gen-2018 Toss, A; Venturelli, M; Sperduti, I; Isca, C; Molinaro, E; Barbieri, E; Piacentini, F; Omarini, C; Cortesi, L; Cascinu, S; Moscetti,
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 1-gen-2018 Toss, A.; Venturelli, Marta; Sperduti, I.; Isca, Chrystel; Barbieri, Elena; Piacentini, F.; Omarini, C.; Cortesi, L.; Cascinu, S.; Moscetti, L.
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 1-gen-2019 Toss, A.; Venturelli, M.; Sperduti, I.; Molinaro, E.; Isca, C.; Barbieri, E.; Piacentini, F.; Omarini, C.; Cortesi, L.; Cascinu, S.; Moscetti, L.
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 1-gen-2019 Palumbo, Patrizia; Draisci, Stefano; Barbolini, Monica; Nasso, Cecilia; Isca, Chrystel; Bocconi, Alessandro; Balduzzi, Sara; Pecchi, Annarita; Galetti, Silvia; Torricelli, Pietro; Piacentini, Federico; Moscetti, Luca; Cascinu, Stefano; Omarini, Claudia
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 1-gen-2020 Omarini, Claudia; Bettelli, Stefania Raffaella; Manfredini, Samantha; Barbolini, Monica; Isca, Chrystel; Cortesi, Giulia; Maiorana, Antonino; Tazzioli, Giovanni; Dominici, Massimo; Piacentini, Federico
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 1-gen-2019 Omarini, C; Palumbo, P; Pecchi, A; Draisci, S; Balduzzi, S; Nasso, C; Barbolini, M; Isca, C; Bocconi, A; Moscetti, L; Galetti, S; Tazzioli, G; Torricelli, P; Cascinu, S; Piacentini, F.
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 1-gen-2020 Nasso, C.; Barbolini, M.; Isca, C.; D'Onofrio, R.; Cortesi, G.; Dominici, M.; Piacentini, F.; Omarini, C.
PROGNOSIS AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY ACCORDING TO HER2 EXPRESSION IN EARLY BREAST CANCER: a retrospective single institution analysis 1-gen-2020 D'Onofrio, R.; Omarini, C.; Barbolini, M.; Nasso, C.; Isca, C.; Dominici, M.; Piacentini, F.
T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis. 1-gen-2022 Omarini, C; Piacentini, F; Sperduti, I; Cerma, K; Barbolini, M; Canino, F; Nasso, C; Isca, C; Caggia, F; Dominici, M; Moscetti, L.